| Field | Row 1 |
|---|---|
| adsh | 0001818382-25-000076 |
| cik | 1818382 |
| name | HUMACYTE, INC. |
| sic | 2836 |
| countryba | US |
| stprba | NC |
| cityba | DURHAM |
| zipba | 27713 |
| bas1 | 2525 EAST NORTH CAROLINA HIGHWAY 54 |
| bas2 | |
| baph | 919-313-9633 |
| countryma | US |
| stprma | NC |
| cityma | DURHAM |
| zipma | 27713 |
| mas1 | 2525 EAST NORTH CAROLINA HIGHWAY 54 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 851763759 |
| former | ALPHA HEALTHCARE ACQUISITION CORP. |
| changed | 20200716 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250513 |
| accepted | 2025-05-13 17:11:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | huma-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001818382-25-000076 | 20250331 | Accounts Receivable Net Current | 300000.0000 | USD | 0 | us-gaap/2024 | Product Or Service= Product And Service Other; | ||
| 0001818382-25-000076 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2487000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 4600000.0000 | USD | 1 | us-gaap/2024 | Contingent Consideration By Type= Earnout Shares; | ||
| 0001818382-25-000076 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -49700000.0000 | USD | 1 | us-gaap/2024 | Contingent Consideration By Type= Earnout Shares; | ||
| 0001818382-25-000076 | 20241231 | Business Combination Contingent Consideration Liability Noncurrent | 71000000.0000 | USD | 0 | us-gaap/2024 | Contingent Consideration By Type= Earnout Shares; | ||
| 0001818382-25-000076 | 20241231 | Cash And Cash Equivalents At Carrying Value | 44937000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20231231 | Common Stock Shares Outstanding | 103673728.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20250331 | Common Stock Shares Outstanding | 155118816.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20250331 | Cost Of Goods And Services Sold | 147000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Finance Lease Liability Current | 2917000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Increase Decrease In Prepaid Expense | -392000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Interest Expense Interest Bearing Liability | 2152000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Other Assets Noncurrent | 1237000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Other Liabilities Noncurrent | 300000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= J D R F Agreement; | ||
| 0001818382-25-000076 | 20250331 | Preferred Stock Shares Authorized | 20000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Prepaid Expense And Other Assets Current | 2742000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Proceeds From Stock Options Exercised | 2000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Property Plant And Equipment Net | 22436000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 1203000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= A V Access; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 13988000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Unallocated Expenses; | ||
| 0001818382-25-000076 | 20241231 | Restricted Cash Noncurrent | 50000000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Revenue Interest Purchase Agreement; | ||
| 0001818382-25-000076 | 20231231 | Stockholders Equity | 13546000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Stockholders Equity | 36043000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 625.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 15514.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Value New Issues | 43046000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value New Issues | 46660000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20241031 | Warrants And Rights Outstanding | 6100000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Subsidiary Sale Of Stock= November2024 Registered Direct Offering; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 19254000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 385000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Accounts Receivable Net Current | 100000.0000 | USD | 0 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001818382-25-000076 | 20250331 | Accounts Payable Current | 5572000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Accounts Receivable Net Current | 180000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20210831 | Business Combination Contingent Consideration Liability Noncurrent | 159400000.0000 | USD | 0 | us-gaap/2024 | Contingent Consideration By Type= Earnout Shares; | ||
| 0001818382-25-000076 | 20250331 | Cash And Cash Equivalents At Carrying Value | 62847000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 95290000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 35057000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001818382-25-000076 | 20241231 | Common Stock Shares Issued | 130027509.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Common Stock Shares Issued | 155118816.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Cost Of Goods And Services Sold | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Depreciation | 1308000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Finance Lease Liability Noncurrent | 12844000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Finance Lease Principal Payments | 603000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Finance Lease Right Of Use Asset | 14966000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Interest Expense Interest Bearing Liability | 1418000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Inventory Net | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Inventory Net | 8020000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Net Income Loss | -31896000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Operating Income Loss | -23184000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 13000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Other Liabilities Current | 60000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Other Liabilities Noncurrent | 983000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Prepaid Expense And Other Assets Current | 2350000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Proceeds From Issuance Of Common Stock | 43396000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20250331 | Proceeds From Issuance Of Common Stock | 47000000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20240331 | Proceeds From Issuance Of Unsecured Debt | 20000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 992000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= A V Access; | ||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 2085000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Direct Expenses; | ||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 3252000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Other Research And Development; | ||
| 0001818382-25-000076 | 20241231 | Restricted Cash Noncurrent | 50209000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product And Service Other; | ||
| 0001818382-25-000076 | 20240331 | Share Based Compensation | 1454000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20231231 | Stockholders Equity | 10000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value New Issues | 370000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= A T M Facility; | ||
| 0001818382-25-000076 | 20240930 | Warrants And Rights Outstanding | 15200000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Subsidiary Sale Of Stock= October2024 Registered Direct Offering; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 12437000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 1080000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 108246008.0000 | shares | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 108246008.0000 | shares | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 131496877.0000 | shares | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Accounts Payable Current | 4490000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Business Combination Contingent Consideration Liability Noncurrent | 70961000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Common Stock Shares Outstanding | 119084353.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20241231 | Common Stock Shares Outstanding | 130027509.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Comprehensive Income Net Of Tax | -31896000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Costs And Expenses | 26578000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Debt Issuance Costs Incurred But Not Yet Paid | 0.0000 | USD | 1 | 0001818382-25-000076 | |||
| 0001818382-25-000076 | 20250331 | Earnings Per Share Basic | 0.2800 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Finance Lease Right Of Use Asset Amortization | 524000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Increase Decrease In Accounts Receivable | 308000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Increase Decrease In Operating Lease Liability | -13000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Increase Decrease In Prepaid Expense | -409000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Net Cash Provided By Used In Financing Activities | 62795000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Net Cash Provided By Used In Financing Activities | 46739000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Net Cash Provided By Used In Investing Activities | -228000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Net Cash Provided By Used In Operating Activities | -27347000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Other Liabilities Noncurrent | 951000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 21264000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 1665000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= External Services; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= P A D; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 227000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Vascular Trauma; | ||
| 0001818382-25-000076 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Share Based Compensation | 2487000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001818382-25-000076 | 20250331 | Stockholders Equity | 682903000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Shares New Issues | 15410000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20241231 | Unsecured Debt Current | 885000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Unsecured Long Term Debt | 64672000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 6432000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 6432000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 12437000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 400000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 385000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 2147000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 100000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 93000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 93000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 131759302.0000 | shares | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 115858000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240930 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Common Stock Shares Outstanding | 155118816.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Comprehensive Income Net Of Tax | 39139000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Cost Of Goods And Services Sold | 100000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001818382-25-000076 | 20240331 | Debt Issuance Costs Incurred But Not Yet Paid | 500000.0000 | USD | 1 | 0001818382-25-000076 | |||
| 0001818382-25-000076 | 20240331 | Depreciation | 1274000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Derivative Liabilities Noncurrent | 3464000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Earnings Per Share Basic | -0.2900 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Earnings Per Share Diluted | 0.2800 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Finance Lease Liability Noncurrent | 13620000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Finance Lease Principal Payments | 687000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Increase Decrease In Accounts Receivable | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Investment Income Interest | 662000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Noncash Contingent Derivative Liability | 1552000.0000 | USD | 1 | 0001818382-25-000076 | |||
| 0001818382-25-000076 | 20241231 | Preferred Stock Shares Authorized | 20000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Proceeds From Issuance Of Common Stock | 370000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= A T M Facility; | ||
| 0001818382-25-000076 | 20250331 | Proceeds From Stock Options Exercised | 56000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 9161000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Payroll And Personnel Expenses; | ||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 19179000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Unallocated Expenses; | ||
| 0001818382-25-000076 | 20250331 | Restricted Cash Noncurrent | 50000000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Revenue Interest Purchase Agreement; | ||
| 0001818382-25-000076 | 20250331 | Restricted Cash Noncurrent | 200000.0000 | USD | 0 | us-gaap/2024 | Restricted Cash And Cash Equivalents Cash And Cash Equivalents= Deposit Account; | ||
| 0001818382-25-000076 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001818382-25-000076 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 517000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20231231 | Stockholders Equity | -537314000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001818382-25-000076 | 20240331 | Stockholders Equity | 26152000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Stockholders Equity | -686015000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Value New Issues | 43044000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Value New Issues | 2000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 2000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 56000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 56000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 1100000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Subsidiary Sale Of Stock= November2024 Registered Direct Offering; | ||
| 0001818382-25-000076 | 20241231 | Accounts Receivable Net Current | 200000.0000 | USD | 0 | us-gaap/2024 | Product Or Service= Product And Service Other; | ||
| 0001818382-25-000076 | 20241231 | Additional Paid In Capital | 633333000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2487000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Assets Current | 73705000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 4593000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Business Combination Contingent Consideration Liability Noncurrent | 21230000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 29000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 80801000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Depreciation | 1274000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001818382-25-000076 | 20240331 | Earnings Per Share Diluted | -0.2900 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Increase Decrease In Accounts Payable | 653000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Interest Expense Nonoperating | 3000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Liabilities | 190541000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Liabilities And Stockholders Equity | 162553000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Net Cash Provided By Used In Investing Activities | -391000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Nonoperating Income Expense | -5318000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Other Assets Noncurrent | 1251000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Proceeds From Issuance Of Common Stock | 0.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= A T M Facility; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 15418000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 15418000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 1430000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Direct Expenses; | ||
| 0001818382-25-000076 | 20241231 | Retained Earnings Accumulated Deficit | -686015000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Retained Earnings Accumulated Deficit | -646876000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Selling General And Administrative Expense | 8136000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20241231 | Stockholders Equity | 13000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20250331 | Stock Issuance Costs Incurred But Not Paid | 340000.0000 | USD | 1 | 0001818382-25-000076 | |||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Shares New Issues | 25000000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20250331 | Unsecured Debt Current | 1700000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Revenue Interest Purchase Agreement; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 1080000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 2147000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Liabilities And Stockholders Equity | 137872000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Accrued Liabilities Current | 9701000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1454000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1454000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20250331 | Assets | 162553000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 545000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001818382-25-000076 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20210831 | Common Stock Shares Issued | 2500000.0000 | shares | 0 | us-gaap/2024 | Counterparty Name= Fresenius Medical Care; Related Party Transactions By Related Party= Related Party; | ||
| 0001818382-25-000076 | 20250331 | Common Stock Value | 16000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Costs And Expenses | 23701000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Finance Lease Right Of Use Asset | 15490000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Finance Lease Right Of Use Asset Amortization | 517000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Increase Decrease In Accounts Payable | -2949000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Net Income Loss | 39139000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001818382-25-000076 | 20250331 | Noncash Contingent Derivative Liability | 0.0000 | USD | 1 | 0001818382-25-000076 | |||
| 0001818382-25-000076 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 14000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Property Plant And Equipment Net | 23063000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 963000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Vascular Trauma; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Materials And Supplies; | ||
| 0001818382-25-000076 | 20250331 | Restricted Cash Noncurrent | 50209000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20231231 | Stockholders Equity | 550850000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20240331 | Stockholders Equity | 595350000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20240331 | Stockholders Equity | -569210000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001818382-25-000076 | 20250331 | Stockholders Equity | 16000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 15514.0000 | shares | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value New Issues | 3000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 2000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Unrealized Gain Loss On Derivatives | 14930000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 6400000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Subsidiary Sale Of Stock= November2024 Registered Direct Offering; | ||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 12400000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Subsidiary Sale Of Stock= October2024 Registered Direct Offering; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 3320000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Accounts Payable Current | 100000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Fresenius Medical Care Deutschland Gmb H; Related Party Transactions By Related Party= Related Party; | ||
| 0001818382-25-000076 | 20250331 | Accounts Receivable Net Current | 488000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Additional Paid In Capital | 682903000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Assets | 137872000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Business Combination Contingent Consideration Liability Noncurrent | 21200000.0000 | USD | 0 | us-gaap/2024 | Contingent Consideration By Type= Earnout Shares; | ||
| 0001818382-25-000076 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 113200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 17910000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Common Stock Shares Outstanding | 130027509.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001818382-25-000076 | 20240331 | Increase Decrease In Accrued Liabilities | -2107000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Increase Decrease In Operating Lease Liability | -14000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Interest Expense Nonoperating | 1816000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Liabilities | 126510000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Liabilities Current | 19954000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Nonoperating Income Expense | 62323000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Operating Income Loss | -26578000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Other Liabilities Current | 238000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Payments To Acquire Property Plant And Equipment | 391000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Proceeds From Issuance Of Common Stock | 2500000.0000 | USD | 2 | us-gaap/2024 | Subsidiary Sale Of Stock= Equity Line Financing; | ||
| 0001818382-25-000076 | 20250331 | Proceeds From Issuance Of Unsecured Debt | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 21264000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 2778000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Other Research And Development; | ||
| 0001818382-25-000076 | 20250331 | Research And Development Expense | 9545000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Payroll And Personnel Expenses; | ||
| 0001818382-25-000076 | 20241231 | Restricted Cash Noncurrent | 200000.0000 | USD | 0 | us-gaap/2024 | Restricted Cash And Cash Equivalents Cash And Cash Equivalents= Deposit Account; | ||
| 0001818382-25-000076 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 147000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001818382-25-000076 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 370000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product And Service Other; | ||
| 0001818382-25-000076 | 20240331 | Share Based Compensation | 1454000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001818382-25-000076 | 20241231 | Stockholders Equity | -52669000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Stockholders Equity | 633333000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001818382-25-000076 | 20250331 | Stockholders Equity | -646876000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001818382-25-000076 | 20240331 | Stock Issuance Costs Incurred But Not Paid | 350000.0000 | USD | 1 | 0001818382-25-000076 | |||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Shares New Issues | 75793.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= A T M Facility; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value New Issues | 46657000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Public Stock Offering; | ||
| 0001818382-25-000076 | 20250331 | Stock Issued During Period Value New Issues | 370000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= A T M Facility; | ||
| 0001818382-25-000076 | 20240331 | Unrealized Gain Loss On Derivatives | 60000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Unsecured Debt Current | 900000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Revenue Interest Purchase Agreement; | ||
| 0001818382-25-000076 | 20250331 | Unsecured Debt Current | 1690000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= November2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 2100000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Subsidiary Sale Of Stock= October2024 Registered Direct Offering; | ||
| 0001818382-25-000076 | 20241231 | Accounts Payable Current | 100000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Fresenius Medical Care Deutschland Gmb H; Related Party Transactions By Related Party= Related Party; | ||
| 0001818382-25-000076 | 20241231 | Accrued Liabilities Current | 11424000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Accrued Liabilities Current | 100000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Fresenius Medical Care Deutschland Gmb H; Related Party Transactions By Related Party= Related Party; | ||
| 0001818382-25-000076 | 20241231 | Assets Current | 47859000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -49731000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Common Stock Value | 13000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Depreciation | 1308000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001818382-25-000076 | 20241231 | Derivative Liabilities Noncurrent | 2415000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Finance Lease Liability Current | 3006000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Increase Decrease In Accrued Liabilities | -2267000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Increase Decrease In Inventories | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Increase Decrease In Inventories | 8020000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Investment Income Interest | 1031000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Liabilities Current | 20029000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Net Cash Provided By Used In Operating Activities | -28601000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Net Income Loss | -31896000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001818382-25-000076 | 20250331 | Net Income Loss | 39139000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Other Liabilities Noncurrent | 300000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= J D R F Agreement; | ||
| 0001818382-25-000076 | 20250331 | Payments To Acquire Property Plant And Equipment | 228000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 1313000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= External Services; | ||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 5453000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= Materials And Supplies; | ||
| 0001818382-25-000076 | 20240331 | Research And Development Expense | 130000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; Product Or Service= P A D; | ||
| 0001818382-25-000076 | 20240331 | Selling General And Administrative Expense | 5314000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20250331 | Share Based Compensation | 2487000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20241231 | Unsecured Long Term Debt | 63354000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001818382-25-000076 | 20210831 | Warrants And Rights Outstanding | 600000.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= October2024 Registered Direct Offering Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001818382-25-000076 | 20250331 | Warrants And Rights Outstanding | 0.0000 | USD | 0 | us-gaap/2024 | Class Of Warrant Or Right= Private Placement Warrants; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Finance Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Finance Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Increase Decrease In Prepaid Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense | The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Proceeds From Issuance Of Unsecured Debt | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Unsecured Debt | The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Cost Of Goods And Services Sold | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Business Combination Contingent Consideration Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Business Combination, Contingent Consideration, Liability, Noncurrent | Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Debt Issuance Costs Incurred But Not Yet Paid | 0001818382-25-000076 | 1 | 0 | monetary | D | C | Debt Issuance Costs Incurred But Not Yet Paid | Debt Issuance Costs Incurred But Not Yet Paid |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Derivative Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Derivative Liability, Noncurrent | Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. |
| Finance Lease Principal Payments | us-gaap/2024 | 0 | 0 | monetary | D | C | Finance Lease, Principal Payments | Amount of cash outflow for principal payment on finance lease. |
| Interest Expense Nonoperating | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Nonoperating | Amount of interest expense classified as nonoperating. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Finance Lease Right Of Use Asset Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Finance Lease, Right-of-Use Asset, Amortization | Amount of amortization expense attributable to right-of-use asset from finance lease. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Other Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Warrants And Rights Outstanding | us-gaap/2024 | 0 | 0 | monetary | I | C | Warrants and Rights Outstanding | Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | 0 | 0 | monetary | D | D | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. |
| Costs And Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Costs and Expenses | Total costs of sales and operating expenses for the period. |
| Finance Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Amount, after accumulated amortization, of right-of-use asset from finance lease. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Restricted Cash Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash, Noncurrent | Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Unrealized Gain Loss On Derivatives | us-gaap/2024 | 0 | 0 | monetary | D | C | Unrealized Gain (Loss) on Derivatives | The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Unsecured Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Unsecured Debt, Current | Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer. |
| Noncash Contingent Derivative Liability | 0001818382-25-000076 | 1 | 0 | monetary | D | C | Noncash Contingent Derivative Liability | Noncash Contingent Derivative Liability |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Depreciation | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation | The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Investment Income Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Interest | Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Proceeds From Issuance Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Finance Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Finance Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from finance lease, classified as current. |
| Stock Issuance Costs Incurred But Not Paid | 0001818382-25-000076 | 1 | 0 | monetary | D | C | Stock Issuance Costs Incurred But Not Paid | Stock Issuance Costs Incurred But Not Paid |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Interest Expense Interest Bearing Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Interest-Bearing Liability | Amount of interest expense on interest-bearing liability. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Unsecured Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | I | C | Unsecured Long-Term Debt, Noncurrent | Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001818382-25-000076 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001818382-25-000076 | 2 | 4 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventory | 0 |
| 0001818382-25-000076 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable | 0 |
| 0001818382-25-000076 | 2 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001818382-25-000076 | 2 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001818382-25-000076 | 2 | 8 | BS | 0 | H | Restricted Cash Noncurrent | us-gaap/2024 | Restricted cash | 0 |
| 0001818382-25-000076 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0001818382-25-000076 | 2 | 10 | BS | 0 | H | Finance Lease Right Of Use Asset | us-gaap/2024 | Finance lease right-of-use assets, net | 0 |
| 0001818382-25-000076 | 2 | 11 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other long-term assets | 0 |
| 0001818382-25-000076 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001818382-25-000076 | 2 | 15 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001818382-25-000076 | 2 | 16 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0001818382-25-000076 | 2 | 17 | BS | 0 | H | Finance Lease Liability Current | us-gaap/2024 | Finance lease obligation, current portion | 0 |
| 0001818382-25-000076 | 2 | 18 | BS | 0 | H | Unsecured Debt Current | us-gaap/2024 | Revenue interest liability, current portion | 0 |
| 0001818382-25-000076 | 2 | 19 | BS | 0 | H | Other Liabilities Current | us-gaap/2024 | Other current liabilities | 0 |
| 0001818382-25-000076 | 2 | 20 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001818382-25-000076 | 2 | 21 | BS | 0 | H | Unsecured Long Term Debt | us-gaap/2024 | Revenue interest liability, net of current portion | 0 |
| 0001818382-25-000076 | 2 | 22 | BS | 0 | H | Business Combination Contingent Consideration Liability Noncurrent | us-gaap/2024 | Contingent Earnout Liability | 0 |
| 0001818382-25-000076 | 2 | 23 | BS | 0 | H | Finance Lease Liability Noncurrent | us-gaap/2024 | Finance lease obligation, net of current portion | 0 |
| 0001818382-25-000076 | 2 | 24 | BS | 0 | H | Derivative Liabilities Noncurrent | us-gaap/2024 | Contingent derivative liability | 0 |
| 0001818382-25-000076 | 2 | 25 | BS | 0 | H | Warrants And Rights Outstanding | us-gaap/2024 | Common stock warrant liabilities | 0 |
| 0001818382-25-000076 | 2 | 26 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other long-term liabilities | 0 |
| 0001818382-25-000076 | 2 | 27 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001818382-25-000076 | 2 | 28 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 11) | 0 |
| 0001818382-25-000076 | 2 | 30 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock, $0.0001 par value; 20,000,000 shares designated as of March 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024 | 0 |
| 0001818382-25-000076 | 2 | 31 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 155,118,816 and 130,027,509 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001818382-25-000076 | 2 | 32 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001818382-25-000076 | 2 | 33 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001818382-25-000076 | 2 | 34 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders equity (deficit) | 0 |
| 0001818382-25-000076 | 2 | 35 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders equity (deficit) | 0 |
| 0001818382-25-000076 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001818382-25-000076 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares designated (in shares) | 0 |
| 0001818382-25-000076 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued (in shares) | 0 |
| 0001818382-25-000076 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding (in shares) | 0 |
| 0001818382-25-000076 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001818382-25-000076 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001818382-25-000076 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued (in shares) | 0 |
| 0001818382-25-000076 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001818382-25-000076 | 4 | 8 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenue | 0 |
| 0001818382-25-000076 | 4 | 10 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of goods sold | 0 |
| 0001818382-25-000076 | 4 | 11 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001818382-25-000076 | 4 | 12 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0001818382-25-000076 | 4 | 13 | IS | 0 | H | Costs And Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001818382-25-000076 | 4 | 14 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0001818382-25-000076 | 4 | 16 | IS | 0 | H | Investment Income Interest | us-gaap/2024 | Interest income | 0 |
| 0001818382-25-000076 | 4 | 17 | IS | 0 | H | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | Change in fair value of Contingent Earnout Liability | 1 |
| 0001818382-25-000076 | 4 | 18 | IS | 0 | H | Unrealized Gain Loss On Derivatives | us-gaap/2024 | Change in fair value of derivatives | 0 |
| 0001818382-25-000076 | 4 | 19 | IS | 0 | H | Interest Expense Nonoperating | us-gaap/2024 | Interest expense | 1 |
| 0001818382-25-000076 | 4 | 20 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total other income (expense), net | 0 |
| 0001818382-25-000076 | 4 | 21 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001818382-25-000076 | 4 | 22 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive income (loss) | 0 |
| 0001818382-25-000076 | 4 | 23 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net income (loss) per share attributable to common stockholders, basic (in dollars per share) | 0 |
| 0001818382-25-000076 | 4 | 24 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, basic (in shares) | 0 |
| 0001818382-25-000076 | 4 | 25 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net income (loss) per share attributable to common stockholders, diluted (in dollars per share) | 0 |
| 0001818382-25-000076 | 4 | 26 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, diluted (in shares) | 0 |
| 0001818382-25-000076 | 5 | 16 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001818382-25-000076 | 5 | 17 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning balance | 0 |
| 0001818382-25-000076 | 5 | 18 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Issuance of common stock (in shares) | 0 |
| 0001818382-25-000076 | 5 | 19 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Issuance of common stock | 0 |
| 0001818382-25-000076 | 5 | 20 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Proceeds from the exercise of stock options (in shares) | 0 |
| 0001818382-25-000076 | 5 | 21 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Proceeds from the exercise of stock options | 0 |
| 0001818382-25-000076 | 5 | 22 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation | 0 |
| 0001818382-25-000076 | 5 | 23 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001818382-25-000076 | 5 | 24 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001818382-25-000076 | 5 | 25 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending balance | 0 |
| 0001818382-25-000076 | 6 | 8 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001818382-25-000076 | 6 | 10 | CF | 0 | H | Depreciation | us-gaap/2024 | Depreciation expense | 0 |
| 0001818382-25-000076 | 6 | 11 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001818382-25-000076 | 6 | 12 | CF | 0 | H | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | Change in fair value of Contingent Earnout Liability | 0 |
| 0001818382-25-000076 | 6 | 13 | CF | 0 | H | Interest Expense Interest Bearing Liability | us-gaap/2024 | Non-cash interest expense | 0 |
| 0001818382-25-000076 | 6 | 14 | CF | 0 | H | Unrealized Gain Loss On Derivatives | us-gaap/2024 | Change in fair value of derivatives | 1 |
| 0001818382-25-000076 | 6 | 15 | CF | 0 | H | Finance Lease Right Of Use Asset Amortization | us-gaap/2024 | Amortization expense | 0 |
| 0001818382-25-000076 | 6 | 16 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Non-cash operating lease costs | 0 |
| 0001818382-25-000076 | 6 | 18 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0001818382-25-000076 | 6 | 19 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventory | 1 |
| 0001818382-25-000076 | 6 | 20 | CF | 0 | H | Increase Decrease In Prepaid Expense | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0001818382-25-000076 | 6 | 21 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0001818382-25-000076 | 6 | 22 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses | 0 |
| 0001818382-25-000076 | 6 | 23 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Operating lease obligation | 0 |
| 0001818382-25-000076 | 6 | 24 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001818382-25-000076 | 6 | 26 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchase of property and equipment | 1 |
| 0001818382-25-000076 | 6 | 27 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0001818382-25-000076 | 6 | 29 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2024 | Proceeds from the issuance and sale of common stock | 0 |
| 0001818382-25-000076 | 6 | 30 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from the exercise of stock options | 0 |
| 0001818382-25-000076 | 6 | 31 | CF | 0 | H | Finance Lease Principal Payments | us-gaap/2024 | Payments of finance lease principal | 1 |
| 0001818382-25-000076 | 6 | 32 | CF | 0 | H | Proceeds From Issuance Of Unsecured Debt | us-gaap/2024 | Proceeds from Revenue Interest Purchase Agreement | 0 |
| 0001818382-25-000076 | 6 | 33 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0001818382-25-000076 | 6 | 34 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net increase in cash, cash equivalents and restricted cash | 0 |
| 0001818382-25-000076 | 6 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash at the beginning of the period | 0 |
| 0001818382-25-000076 | 6 | 36 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash at the end of the period | 0 |
| 0001818382-25-000076 | 6 | 38 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | Purchase of property and equipment in accounts payable and accrued expenses | 0 |
| 0001818382-25-000076 | 6 | 39 | CF | 0 | H | Stock Issuance Costs Incurred But Not Paid | 0001818382-25-000076 | Unpaid issuance costs in connection with public offering | 0 |
| 0001818382-25-000076 | 6 | 40 | CF | 0 | H | Debt Issuance Costs Incurred But Not Yet Paid | 0001818382-25-000076 | Unpaid transaction costs related to revenue interest purchase agreement | 0 |
| 0001818382-25-000076 | 6 | 41 | CF | 0 | H | Noncash Contingent Derivative Liability | 0001818382-25-000076 | Debt discount from embedded contingent derivative liability | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |